Compare WSC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSC | APGE |
|---|---|---|
| Founded | 1944 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.7B |
| IPO Year | 2015 | 2023 |
| Metric | WSC | APGE |
|---|---|---|
| Price | $21.36 | $134.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $24.14 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $2,281,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | $51.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.91 | $35.39 |
| 52 Week High | $29.77 | $134.88 |
| Indicator | WSC | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 76.88 |
| Support Level | $21.40 | $134.03 |
| Resistance Level | $22.87 | $134.88 |
| Average True Range (ATR) | 1.12 | 0.16 |
| MACD | -0.14 | -0.57 |
| Stochastic Oscillator | 6.62 | 88.54 |
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.